Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL466958 | 0.94 | CHRM2 (0.88) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL19598795 | 0.69 | RAB9A (0.86) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL12950992 | 0.68 | CHRM2 (0.50) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL2207458 | 0.68 | CHRM2 (0.51) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL14980754 | 0.68 | CHRM2 (0.51) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL12951373 | 0.67 | SIGMAR1 (0.50) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL298670 | 0.67 | CHRM2 (0.49) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| Bromide SCHEMBL11203229 | 0.66 | CHRM2 (0.49) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL12950819 | 0.65 | SIGMAR1 (0.48) | CHRM2CHRM4CHRM5ADRA2AADRA2B | |
| SCHEMBL11196119 | 0.65 | IGF1R (0.49) | CHRM2CHRM4CHRM5ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314018-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | Baylor College of Medicine (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230355711-A1 | VIMENTIN AND FRAGMENTS OR DERIVATIVES THEREOF FOR CORONAVIRUS TREATMENT AND PREVENTION | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-11-09 | — | — | US | claimed |
| US-20230210902-A1 | SARS-COV-2-SPECIFIC T CELLS | NATIONAL INSTITUTES OF HEALTH | 2023-07-06 | — | — | US | claimed |
| US-20220401553-A1 | PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO. KG (DE) | 2022-12-22 | — | — | US | claimed |
| WO-2022213076-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | BAYLOR COLLEGE OF MEDICINE (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3906970-B1 | PARAPOXVIRUS FOR CONDITIONING AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO KG (DE) | 2022-07-06 | — | — | EP | claimed |
| US-20220193204-A1 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-23 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250149121-A1 | DETECTION OF PEPTIDE STRUCTURES FOR DIAGNOSING AND TREATING SEPSIS AND COVID | VENN BIOSCIENCES CORPORATION | 2025-05-08 | — | — | US | disclosed |
| EP-4547334-A1 | SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12208110-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240350596-A1 | DOWNREGULATION OF CIRCULATING GHRELIN AND THERAPEUTIC APPLICATIONS THEREOF | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2024-10-24 | — | — | US | disclosed |
| CN-118766947-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
| WO-2000041684-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF DEPRESSION | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208110-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS1, SGMS2 | CHRM2 4289/4885CHRM4 3633/4885CHRM5 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.